Human fascioliasis treated with triclabendazole (Fasinex®) for the first time

Wessely, Karl; Reischig, H.L.; Heinerman, M.; Stempka, R.

doi:10.1016/0035-9203(88)90222-2

Cited by 37 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, patients received 20 mg/kg TCZ as two doses of 10 mg/kg administered after a fatty meal 12 hr apart. The rationale of this dosage which exceeded the dosage used in previous studies [15][16][17] was to achieve maximum efficacy in our patients with a recent infection who had already proved refractory to other antihelminthic drugs. A previous therapy trial using a single dose of 10 mg/kg TCZ yielded a cure rate of 79% in asymptomatic patients.…”

Section: Methodsmentioning

confidence: 96%

The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.

Millán

Mull²,

Freise³

et al. 2000

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Current chemotherapy for the treatment of infections caused by the liver fluke Fasciola hepatica is not satisfactory. Therefore, the efficacy and tolerability of triclabendazole (TCZ) was assessed for this indication. Eightytwo patients (51 female, 31 male, age 15-81 yr, mean 42 yr) with chronic or latent F. hepatica infection refractory to previous anti-helminthic chemotherapy were enrolled in a 60-day open, non-comparative trial. Patients received 20 mg/kg TCZ as two doses of 10 mg/kg administered after food 12 hr apart. Efficacy of treatment was assessed by stool microscopy, determination of Fasciola excretory-secretory antigen (FES) in feces, and by ultrasonography (US) which were systematically performed pre-therapy and on Days 1-7, 15, 30, and 60 post-therapy. For continuous safety assessment, patients were hospitalized during the first week after therapy and then monitored at home for the appearance of any adverse events. Clinical chemistry and hematology tests were carried out on Days 1, 3, 7, 15, and 60, and whenever an adverse effect occurred possibly related to therapy. Seventy-one (92.2%) of the 77 patients who completed the 60-day follow-up period became egg-negative. Efficacy of therapy was supported by the disappearance or decrease of FES antigen and of ultrasonography abnormalities. In the 6 remaining patients, parasitological cure was achieved by another single TCZ dose of 10 mg/kg on Day 60.

show abstract

Section: Methodsmentioning

confidence: 96%

The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.

Millán

Mull²,

Freise³

et al. 2000

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…In our study, the common presentations were similar to those reported by Farid and others 3 and Wessely and others. 28 The patients had weekly checkups after treatment over the course of 3 months. At the end of the follow-up period, physical examination revealed normalization of the liver and the spleen.…”

Section: Resultsmentioning

confidence: 99%

Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from Commiphora molmol (myrrh).

Massoud

Sisi²,

Salama³

2001

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Myrrh (from the stem of the Commiphora molmol tree) is an oleo gum resin that may prove efficacious for the treatment of fascioliasis. We studied 7 patients who were passing Fasciola eggs in their stools and treated them with myrrh. The drug (a formulation consisting of 8 parts of resin and 3.5 parts of volatile oils, all extracted from myrrh) was given in a dose of 12 mg/kg per day for 6 consecutive days in the morning on an empty stomach. Patients were followed for 3 months. The therapy proved to be effective, with pronounced improvement of the general condition and amelioration of all symptoms and signs. A dramatic drop in the egg count was detected at the end of treatment. Eggs were no longer detectable in the feces 3 weeks after treatment and after a follow-up period of 3 months. High eosinophilic counts, elevated liver enzymes, and Fasciola antibody titers returned to nearly normal. No signs of toxicity or adverse effects were observed. We conclude that the formulation of myrrh is safe, well tolerated, and effective for treating fascioliasis.

show abstract

“…The veterinary formulation has been shown safe and tolerable in different countries worldwide since 1986, when it was fi rst used in humans (32) (33) as an alternative therapy in view of the ineffi cacy and low tolerability of other drugs. An exhaustive literature review with no language restriction produced a total of 554 (441 adults and 113 children) documented cases between 1986 and 2002 from Germany (32) (33) (61) , Switzerland (62) , France (63) (64) , Belgium (41) , Australia (29) , Venezuela (65) , Spain (66) (67) (68) , the US (69) , Japan (24) , Iran (45) (70) , Chile, (53) and Egypt (28) (44) (54) (55) , that received the veterinary formulation with no or minimal adverse events.…”

Section: Discussionmentioning

confidence: 99%

“…The veterinary TCBZ formulation (Fasinex®), successfully used for the fi rst time in 1986, has proven to be effective and tolerable in humans (32) (33) .…”

Section: Methodsmentioning

confidence: 99%

“…Triclabendazole, or 5-chloro-6-(2,3-dichlorophenoxy)-2[methylthio] benzimidazole, acts against the microtubedependent secretory processes in F. hepatica, was first used in animals in 1983 and humans in 1986 (32) (33) , and has a well-established therapeutic use in human fascioliasis and paragonimiasis (34) . The compound represents the fi rstline treatment against fascioliasis in different regions of the world (23) (24) (25) (26) (27) (28) (29) (32) (33) , and is recommended by the World Health Organization (WHO) as the fi rst-line drug in all cases of fascioliasis (35) .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children

Maco

Marcos

Delgado³

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica, involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the effi cacy and tolerability of 2 schemes of TCBZ. Methods: Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of effi cacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment. Results: A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic. Conclusions: The tested scheme was effi cacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting.

show abstract

Human fascioliasis treated with triclabendazole (Fasinex®) for the first time

Cited by 37 publications

References 8 publications

The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.

The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.

Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from Commiphora molmol (myrrh).

Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children

Contact Info

Product

Resources

About